Goldenwell Biotech, Inc. (GWLL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Goldenwell Biotech, Inc. (GWLL) trades at $0.70 with AI Score 45/100 (Grade C). Goldenwell Biotech, Inc. is a nutraceutical and dietary supplement company based in the United States. Market cap: $69.3M, Sector: Consumer defensive.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for GWLL: GWLL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GWLL against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GWLL: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Goldenwell Biotech, Inc. (GWLL) Consumer Business Overview
Goldenwell Biotech, Inc. is a US-based nutraceutical company focused on developing dietary supplements, including peptide and collagen-based products, operating in the competitive packaged foods industry. With a small team and ongoing product development, Goldenwell Biotech seeks to establish a foothold in the health and wellness market.
What Is the Investment Thesis for GWLL?
Goldenwell Biotech, Inc. presents a high-risk, high-reward investment opportunity due to its early stage and focus on nutraceuticals. The company's potential lies in the successful development and commercialization of its five key products, targeting growing health and wellness markets. With a market capitalization of $69.3M, the company's valuation is highly sensitive to product development milestones and market acceptance. Key value drivers include positive clinical trial results (if applicable), regulatory approvals, and successful product launches. However, the company's negative P/E ratio of -1347.95 and a profit margin of -120.5% indicate significant financial challenges. The high beta of 6.23 suggests extreme volatility. The company's future success hinges on securing additional funding, navigating regulatory hurdles, and effectively competing in the crowded nutraceutical market. Upcoming catalysts include product development updates and potential partnerships. Potential risks include failure to obtain regulatory approvals, competition from established players, and the need for additional capital.
Based on FMP financials and quantitative analysis
GWLL Key Highlights
Market capitalization of $69.3M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -1347.95 reflects the company's current lack of profitability and ongoing investment in product development.
- Gross margin of 100.1% suggests strong pricing power on existing products, but this may not be sustainable as the company scales.
- Profit margin of -120.5% highlights the significant expenses associated with research and development and the lack of revenue generation.
- Beta of 6.23 indicates that the stock is significantly more volatile than the market, reflecting the high-risk nature of the investment.
Who Are GWLL's Competitors?
GWLL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARZTY Aryzta AG | $5.39 | -5.85% | $1.42B | 43 |
| AUDYF Ausnutria Dairy Corporation Ltd | $0.36 | +0.00% | $640M | 47 |
| GKSDF Grupo KUO, S.A.B. de C.V. | $1.90 | +0.00% | $827M | 44 |
| OCGPF Oceana Group Limited | $3.00 | +0.00% | $359M | 45 |
| ORENF Origin Enterprises plc | $4.86 | +0.00% | $522M | 48 |
| BUBSF Bubs Australia Limited | $0.08 | +0.00% | $69.2M | 53 |
| LFVN LifeVantage Corporation | $6.58 | +1.31% | $83.1M | 77 |
| FTLF FitLife Brands, Inc. | $10.01 | -2.20% | $94.0M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GWLL's Key Strengths?
Focus on innovative nutraceutical formulations.
- Potential for strong brand recognition.
- Proprietary technology and intellectual property.
- High gross margin.
What Are GWLL's Weaknesses?
Small size and limited resources.
- Lack of established brand recognition.
- Dependence on successful product development.
- Negative profitability and high operating expenses.
What Could Drive GWLL Stock Higher?
Product development updates on JI MAI—bovine cardiac vascular active peptide.
- Potential partnerships with established nutraceutical companies.
- Regulatory approvals for DNA repair tablets.
- Increasing consumer awareness of health and wellness.
- Expansion into new markets and product lines.
What Are the Key Risks for GWLL?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for its products.
- Intense competition from established players in the nutraceuticals market.
- Need for additional capital to fund product development and marketing.
- Limited financial resources and operating history.
- Volatility associated with OTC market trading.
What Are the Growth Opportunities for GWLL?
- Expansion into New Product Lines: Goldenwell Biotech has the opportunity to expand its product lines beyond its current focus on peptides and collagen. The global nutraceuticals market is projected to reach $500 billion by 2028, offering significant potential for growth. By developing new products targeting specific health concerns, such as immune support, cognitive function, and weight management, Goldenwell Biotech can diversify its revenue streams and attract a broader customer base. This expansion could be achieved through internal research and development or through strategic acquisitions of smaller companies with complementary product portfolios. Timeline: 2-3 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with established players in the nutraceuticals industry can provide Goldenwell Biotech with access to distribution channels, marketing expertise, and additional funding. Collaborating with research institutions and universities can accelerate product development and enhance the company's scientific credibility. These partnerships can also help Goldenwell Biotech navigate the complex regulatory landscape and gain access to international markets. The nutraceutical market is highly fragmented, and strategic alliances can be crucial for gaining a competitive edge. Timeline: Ongoing.
- E-commerce and Direct-to-Consumer Sales: Establishing a strong online presence and focusing on direct-to-consumer sales can help Goldenwell Biotech bypass traditional retail channels and reach a wider audience. The global e-commerce market is experiencing rapid growth, and consumers are increasingly purchasing health and wellness products online. By developing a user-friendly website, implementing effective digital marketing strategies, and offering personalized customer service, Goldenwell Biotech can build brand awareness and drive sales. This approach also allows the company to collect valuable customer data and tailor its product offerings to meet specific needs. Timeline: 1 year.
- International Market Expansion: Expanding into international markets, particularly in Asia and Europe, represents a significant growth opportunity for Goldenwell Biotech. The global nutraceuticals market is experiencing strong growth in these regions, driven by increasing disposable incomes and a growing awareness of health and wellness. By adapting its products to meet local preferences and regulatory requirements, Goldenwell Biotech can tap into these lucrative markets. This expansion could be achieved through partnerships with local distributors or by establishing a direct presence in key markets. Timeline: 3-5 years.
- Focus on Personalized Nutrition: The trend towards personalized nutrition is gaining momentum, with consumers increasingly seeking products tailored to their individual needs and genetic makeup. Goldenwell Biotech can capitalize on this trend by developing personalized nutraceutical solutions based on individual health profiles and genetic testing. This approach requires investing in advanced data analytics and developing customized formulations. By offering personalized nutrition solutions, Goldenwell Biotech can differentiate itself from competitors and attract a loyal customer base. The personalized nutrition market is projected to reach $25 billion by 2027. Timeline: 2-3 years.
What Threats Does GWLL Face?
- Intense competition from established players.
- Regulatory hurdles and compliance requirements.
- Potential for product liability claims.
- Economic downturn and reduced consumer spending.
What Are GWLL's Competitive Advantages?
- Proprietary formulations and intellectual property protection.
- Potential for strong brand recognition and customer loyalty.
- Focus on innovative and scientifically-backed ingredients.
- Strategic partnerships with research institutions and distributors.
What Does GWLL Do?
Goldenwell Biotech, Inc., incorporated in 2019 and based in Hudson, Ohio, operates within the consumer defensive sector, specifically focusing on the development and potential commercialization of nutraceutical and dietary supplements. The company's core business revolves around creating products aimed at improving health and wellness through innovative formulations. Currently, Goldenwell Biotech is developing five key products: JI MAI—bovine cardiac vascular active peptide, cartilage peptide (a type II collagen peptide), Double Proline AG 3D active collagen peptide, DNA repair tablets, and sugar master tablets. These products target various health concerns, including cardiovascular health, joint health, and DNA repair. Founded with the vision of providing advanced health solutions through nutraceuticals, Goldenwell Biotech is still in its early stages of development. The company's small size, with only three employees, reflects its current focus on research and product development. The location in Twinsburg, Ohio, provides access to resources and potential partnerships within the broader healthcare and biotechnology ecosystem. As Goldenwell Biotech continues to develop its product pipeline, its success will depend on its ability to navigate the regulatory landscape, secure funding, and effectively market its products to consumers.
What Products and Services Does GWLL Offer?
- Develops nutraceutical and dietary supplements.
- Focuses on peptide and collagen-based products.
- Targets health concerns such as cardiovascular and joint health.
- Conducts research and development for new formulations.
- Aims to improve health and wellness through innovative products.
- Seeks regulatory approvals for its products.
- Markets and sells its products to consumers.
How Does GWLL Make Money?
- Develops and patents novel nutraceutical formulations.
- Manufactures or outsources the production of its products.
- Markets and sells its products through online channels and potential partnerships.
- Generates revenue through the sale of its nutraceutical and dietary supplements.
What Industry Does GWLL Operate In?
Goldenwell Biotech operates within the consumer defensive sector, specifically in the packaged foods industry, which includes the rapidly growing nutraceuticals and dietary supplements market. This market is driven by increasing consumer awareness of health and wellness, an aging population, and a growing interest in preventative healthcare. The industry is highly competitive, with established players like ARZTY (Archer Daniels Midland Co), AUDYF (Associated British Foods PLC), GKSDF ( গ্রুপের কুইন স্লিম), OCGPF (Origin Agritech Ltd), and ORENF (Orennia Corp) as well as numerous smaller companies vying for market share. Goldenwell Biotech's success depends on its ability to differentiate its products, effectively market to its target audience, and navigate the complex regulatory landscape.
Who Are GWLL's Key Customers?
- Health-conscious consumers seeking to improve their overall well-being.
- Individuals with specific health concerns, such as cardiovascular or joint issues.
- Consumers interested in preventative healthcare and natural remedies.
- Athletes and fitness enthusiasts looking to enhance their performance and recovery.
Company Profile
Goldenwell Biotech, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Hudson, US. The company is led by CEO Shuang Liu. GWLL has traded publicly since 2022.
Goldenwell Biotech, Inc. (GWLL) Valuation Context
Valued at $69.3M, GWLL is classified as a micro-cap stock. Relative to its peer group, GWLL's quantitative score of 45/100 is roughly in line with the peer average of 45/100.
Key Financial Metrics
Return on equity for Goldenwell Biotech, Inc. stands at 96.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Goldenwell Biotech, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.28 places it in the safe zone, indicating low near-term bankruptcy risk.
GWLL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on innovative nutraceutical formulations.
- Potential for strong brand recognition.
- Proprietary technology and intellectual property.
- High gross margin.
Bear Case
- Small size and limited resources.
- Lack of established brand recognition.
- Dependence on successful product development.
- Negative profitability and high operating expenses.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
GWLL Latest News
No recent news available for GWLL.
GWLL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GWLL.
Price Targets
Wall Street price target analysis for GWLL.
GWLL MoonshotScore
What does this score mean?
The MoonshotScore rates GWLL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Shuang Liu
CEO
Shuang Liu is the CEO of Goldenwell Biotech, Inc. Information regarding Shuang Liu's background is limited, but as CEO, they are responsible for the overall strategic direction and management of the company. With a focus on the nutraceutical and dietary supplement business, Shuang Liu leads the development and commercialization of innovative health and wellness products. Their leadership is crucial for navigating the competitive landscape and achieving the company's growth objectives.
Track Record: As CEO of Goldenwell Biotech, Shuang Liu is responsible for overseeing the development of five key products, including JI MAI—bovine cardiac vascular active peptide, cartilage peptide, and Double Proline AG 3D active collagen peptide. Their success will be measured by the company's ability to secure regulatory approvals, establish strategic partnerships, and generate revenue from its product portfolio. Given the company's early stage, it is too soon to fully assess Shuang Liu's track record.
GWLL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Goldenwell Biotech may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Companies in this tier are often early-stage ventures or those facing financial difficulties. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and investor protection.
- Higher risk of business failure or delisting.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the company's capital structure and funding needs.
- Consult with a qualified financial advisor.
- Company is registered in the United States.
- Company has a website and contact information.
- Company is developing multiple products.
- Company has a small team of employees.
GWLL Consumer Defensive Stock FAQ
What does the AI Score mean for GWLL?
GWLL holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Goldenwell Biotech, Inc. is a nutraceutical and dietary supplement company based in the United States. They are currently developing five products focused on peptides, collagen, and DNA repair.
What does Goldenwell Biotech, Inc. do?
Goldenwell Biotech, Inc. is a nutraceutical and dietary supplement company focused on developing and commercializing innovative health and wellness products. The company is currently developing five key products, including peptide and collagen-based supplements targeting cardiovascular health, joint health, and DNA repair.
What do analysts say about GWLL stock?
As of March 16, 2026, there is no available analyst coverage for Goldenwell Biotech, Inc. (GWLL). The company's micro-cap status and OTC listing may limit its visibility to institutional investors and research firms. Investors should conduct their own independent research and due diligence before investing in GWLL. Key valuation metrics include market capitalization, revenue growth (if any), and profitability.
What are the main risks for GWLL?
Investing in Goldenwell Biotech, Inc. (GWLL) carries significant risks due to its early stage, OTC listing, and limited financial resources. Key risks include the failure to obtain regulatory approvals for its products, intense competition from established players in the nutraceuticals market, and the need for additional capital to fund product development and marketing.
What are the key factors to evaluate for GWLL?
Goldenwell Biotech, Inc. (GWLL) holds an AI score of 45/100 (low). presents a high-risk, high-reward investment opportunity due to its early stage and focus on nutraceuticals. Not financial advice.
How frequently does GWLL data refresh on this page?
GWLL's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GWLL's recent stock price performance?
Goldenwell Biotech, Inc. (GWLL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative nutraceutical formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GWLL overvalued or undervalued right now?
Goldenwell Biotech, Inc. (GWLL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GWLL before investing?
Before investing in Goldenwell Biotech, Inc. (GWLL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Goldenwell Biotech, Inc.
- OTC market investments are highly speculative.